Home › NDC Lookup › RxCUI directory › RxCUI 1657746

Pembrolizumab 50 MG Injection — RxCUI 1657746

RxNorm drug concept · Semantic clinical drug
RxCUI 1657746 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1657746
Official namePembrolizumab 50 MG Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped1
Package NDCs mapped2
Reported Medicaid activity (SDUD)51,156 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Pembrolizumab Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Great question — it's a very different approach. Chemo directly attacks fast-growing cells, including cancer cells. Pembrolizumab is immunotherapy: it doesn't target the cancer its...
  • What exactly is pembrolizumab and how is it different from regular chemotherapy?
  • Each infusion takes about 30 minutes once it's running, though you'll spend extra time at the clinic for preparation and monitoring. Depending on your treatment plan, it's given ev...
  • How often will I need to come in for infusions, and how long does each one take?
📖 Read our full Pembrolizumab Injection guide →

🕸️ Concept Web — How Pembrolizumab 50 MG Injection Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Pembrolizumab 50 MG Injection RxCUI 1657746

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Pembrolizumab 1547545
  2. Dose forms 4

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Pembrolizumab Injection 1657745
    • Pembrolizumab Injectable Product 1547547
    • Injection 1649574
    • Injectable Product 1151126
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Pembrolizumab 50 MG 1657744

Showing up to 8 concepts per family — 6 of 6 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Pembrolizumab 50 MG SCDC · 1657744
  • Pembrolizumab Injection SCDF · 1657745
  • Pembrolizumab Injectable Product SCDG · 1547547

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 1657746 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00006-3026-02 1 VIAL in 1 CARTON (0006-3026-02) / 4 mL in 1 VIAL (0006-30... KEYTRUDA Merck Sharp & Dohme LLC 2015-01-15
00006-3026-04 2 VIAL in 1 CARTON (0006-3026-04) / 4 mL in 1 VIAL (0006-30... KEYTRUDA Merck Sharp & Dohme LLC 2019-08-01
Observed labelers: Merck Sharp & Dohme LLC (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J9271 Inj pembrolizumab 2 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.